Here is some pretty interesting news from Clarient:

Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study suggest that the Clarient Insight® Dx Pulmotax™ assay may effectively predict which lung cancer patients will respond favorably to chemotherapy. The study, titled “TLE3 expression is predictive of response to chemotherapy in NSCLC,” included 368 samples from carcinoma patients. The majority of advanced-stage patients who were treated with chemotherapy received a treatment regimen containing a taxane class agent.

Pulmotax is a single antibody immunohistochemistry test created to detect the expression of TLE3 in non-small cell lung cancer (NSCLC). Prior data have linked TLE3 expression specifically to response to taxane therapy in breast and ovarian carcinoma patients. The study was presented yesterday at the annual meeting of the American Association of Cancer Research (AACR) in Washington, D.C. by Douglas T. Ross, M.D., Ph.D., Chief Scientific Officer of Clarient.

The study summary and results may be found at http://www.clarientinc.com/Pulmotax.

Read More…

Dear Colleague,

You have arrived here because you have an interest in digital pathology and its potential impact on healthcare. Don’t worry, you are not alone!

Recently, I was at USCAP in Washington DC and the clear message there was that digital pathology was on the ascendency – as it well should be. There is enormous promise and benefit from digital pathology to help make diagnosis more accurate through ease of collaboration (slide sharing), more effective image management, and more accurate, objective image analysis related to tissue morphology or biomarker expression.

Every 6 years or so, I have noticed that there is a new “disruptive” technology that begins to take hold, and make a true impact whether it is in translational research or clinical diagnostics (or both!). Based on all of the early signs, digital pathology looks like it very well could be the “next big thing.”

Thank you for stopping by Digital Pathology Insights, and please stop back often, as we will have updated content related to digital pathology, and more importantly, it’s impact on personalized medicine and our daily lives.

Warmest Regards,

Peter Duncan
Director of Marketing and Business Development
pduncan@definiens.com
Definiens